Auckland

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Amyloidosis3 trials
• High blood pressure2 trials

Phase

• Phase 12 trials
• Phase 32 trials
• Phase 2/31 trial

Status

• Recruiting2 trials
• Completed1 trial
• Enrolling by invitation1 trial
• Not yet recruiting1 trial

Lead sponsor

• Alnylam Pharmaceuticals2 trials
• Intellia Therapeutics2 trials
• Antlia Bioscience, Inc1 trial

Running trials

• Not yet recruiting

  Study of AB-110 in Healthy and Hypertensive Participants

  NCT07916961· Phase 1· Antlia Bioscience, Inc· Source

  Contact: Hanna Kwak

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Enrolling by invitation

  Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

  NCT05697861· Phase 2/3· Intellia Therapeutics· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• High blood pressure2 recruiting

Closed trials

• Completed

  Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

  NCT04601051· Phase 1· Intellia Therapeutics· Source